Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | GFER | P55789 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.34 |
| ▸ | RGS12 | O14924 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | RPS6KA2 | Q15349 | 6/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL832505 | 0.99 | MAPT (0.39) | MAPTKDM4EGFERALDH1A1TDP1 | |
| SCHEMBL831453 | 0.86 | KDM4E (0.35) | MAPTKDM4EGFERALDH1A1TDP1 | |
| SCHEMBL831803 | 0.72 | KDM4E (0.44) | MAPTKDM4EGFERALDH1A1MEN1 | |
| SCHEMBL12477091 | 0.70 | KDM4E (0.47) | MAPTKDM4EGFERALDH1A1MEN1 | |
| SCHEMBL30856700 | 0.69 | KDM4E (0.65) | MAPTKDM4EGFERALDH1A1TDP1 | |
| SCHEMBL202597 | 0.64 | KDM4E (0.37) | KDM4EALDH1A1HTTHPGD | |
| SCHEMBL832130 | 0.64 | ALDH1A1 (0.51) | MAPTKDM4EGFERALDH1A1TDP1 | |
| SCHEMBL3577361 | 0.63 | MCHR1 (0.44) | MAPTKDM4EGFERHTR2B | |
| SCHEMBL831804 | 0.63 | KDM4E (0.44) | MAPTKDM4EGFERALDH1A1TDP1 | |
| SCHEMBL831976 | 0.61 | KDM4E (0.35) | MAPTKDM4EGFERALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288376-B2 | Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use | SANOFI (FR) | 2012-10-16 | — | — | US | disclosed |
| US-20120122852-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2012-05-17 | — | — | US | disclosed |
| US-8143248-B2 | Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| EP-1987010-B1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2010-04-07 | — | — | EP | disclosed |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-12 | — | — | US | disclosed |
| EP-1987010-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007088277-A1 | TRICYCLIC Ν-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122852-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | CYP3A5, CYP2C8, CYP3A43 | MAPT 3000/4885KDM4E 1876/4885GFER 2368/4885 |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | CYP3A5, CYP2C8, PAICS | MAPT 3347/4885KDM4E 1797/4885GFER 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.